Kwang Dong Pharmaceutical Co., Ltd.

A009290

KR7009290008

Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 03:30:00 17/05/2024 am IST			5-day change	1st Jan Change
6,880 ^KRW	+0.88%		+1.18%	-7.40%

18/03	Kwang Dong Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
29/01	Zhaoke Ophthalmology Grants Kwangdong Pharma Rights to Distribute Eye Drop in Korea	MT

Kwang Dong Pharmaceutical Co., Ltd. authorizes a Buyback Plan.

April 11, 2023

The Board of Directors of Kwang Dong Pharmaceutical Co., Ltd. has authorized a buyback plan on April 11, 2023.

Latest news about Kwang Dong Pharmaceutical Co., Ltd.

Kwang Dong Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	18/03	CI
Zhaoke Ophthalmology Grants Kwangdong Pharma Rights to Distribute Eye Drop in Korea	29/01	MT
Bioleaders Corporation announced that it has received KRW 2 billion in funding from Kwang Dong Pharmaceutical Co., Ltd.	02/01	CI
Bioleaders Corporation announced that it expects to receive KRW 2 billion in funding from Kwang Dong Pharmaceutical Co., Ltd.	29/12	CI
Kwang Dong Pharmaceutical Co., Ltd. agreed to acquire a 58.73% stake in BL Healthcare Corp. from BL Healthcare Corp. for KRW 30 billion	29/12	CI
Kwang Dong Pharmaceutical Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11	CI
Kwang Dong Pharmaceutical Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/23/14	CI
Tranche Update on Kwang Dong Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on April 11, 2023.	30/23/30	CI
Kwang Dong Pharmaceutical Co., Ltd.'s Equity Buyback announced on April 11, 2023, has closed with 1,000,000 shares, representing 2.43% for KRW 6,228.66 million.	28/23/28	CI
Kwang Dong Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/23/15	CI
Kwang Dong Pharmaceutical Co., Ltd. announces an Equity Buyback for 1,000,000 shares.	11/23/11	CI
Kwang Dong Pharmaceutical Co., Ltd. authorizes a Buyback Plan.	11/23/11	CI
Zhaoke Ophthalmology Grants Kwangdong Pharma Rights to Commercialize Myopia Drug in South Korea	27/23/27	MT
Kwang Dong Pharmaceutical Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	14/22/14	CI
Kwang Dong Pharmaceutical Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	16/22/16	CI
Kwang Dong Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	16/22/16	CI
Kwang Dong Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	17/22/17	CI
Kwang Dong Pharmaceutical Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	15/21/15	CI
Oxford Cancer Biomarkers Ltd announced that it has received funding from Kwang Dong Pharmaceutical Co., Ltd.	03/19/03	CI
Tranche Update on Kwang Dong Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on December 6, 2018.	05/19/05	CI
Tranche Update on Kwang Dong Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on December 6, 2018.	05/19/05	CI
Kwang Dong Pharmaceutical Co., Ltd.'s Equity Buyback announced on December 6, 2018 has closed with 1,000,000 shares, representing 1.91% for KRW 7,098.83 million.	05/19/05	CI
Kwang Dong Pharmaceutical Co., Ltd. announces an Equity Buyback.	06/18/06	CI
Kwang Dong Pharmaceutical Co., Ltd. authorizes a Buyback Plan.	06/18/06	CI
Kwang Dong Pharmaceutical Co., Ltd.(KOSE:A009290) dropped from KOSPI 200 Index	14/18/14	CI

Chart Kwang Dong Pharmaceutical Co., Ltd.

Duration

Period

Chart Kwang Dong Pharmaceutical Co., Ltd.

More charts

Kwangdong Pharmaceutical Co Ltd is a Korea-based company principally engaged in the manufacturing and distribution of pharmaceuticals. The Company operates its business through five segments. The Mineral Water Business segment supplies drinking spring water under Samdasoo brand. The Distribution Business segment distributes health drinks under brand names of Vita500 and Corn Silk Tea. The Pharmacy Business segment provides Chinese prescription cold medicines, hypertension medicines, cerebral apoplexy medicines and health drinks. The Hospital Business segment offers anticancer agents, blood vessel adjuvants, vitamin D injections and others. The Other segment provides products which not covered by Pharmacy, Hospital and Distribution segments.

Sector

Pharmaceuticals

Calendar

13/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
KWANG DONG PHARMACEUTICAL CO., LTD.	-7.40%	203M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+21.59%	44.15B
OTSUKA HOLDINGS CO., LTD.	+23.03%	23.02B
SANDOZ GROUP AG	+18.22%	15.33B
CIPLA LIMITED	+12.26%	13.74B
ZYDUS LIFESCIENCES LIMITED	+52.55%	12.16B
ONO PHARMACEUTICAL CO., LTD.	-10.02%	6.84B
THE MEDICINES COMPANY	-0.05%	6.79B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+13.88%	5.66B

Generic Pharmaceuticals